

CCM2 deficient endothelial cells undergo a ROCK dependent reprogramming into senescence associated secretory phenotype

Daphné Raphaëlle Vannier, Apeksha Shapeti, Florent Chuffart, Emmanuelle Planus, Sandra Manet, Paul Rivier, Olivier Destaing, Corinne Albiges-Rizo, Hans van Oosterwyck, Eva Faurobert

▶ To cite this version:

Daphné Raphaëlle Vannier, Apeksha Shapeti, Florent Chuffart, Emmanuelle Planus, Sandra Manet, et al.. CCM2 deficient endothelial cells undergo a ROCK dependent reprogramming into senescence associated secretory phenotype. Angiogenesis, 2021, 10.1007/s10456-021-09809-2. hal-03437734

HAL Id: hal-03437734 https://hal.science/hal-03437734

Submitted on 20 Nov 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

CCM2 deficient endothelial cells undergo a ROCKs dependent reprogramming into senescence associated secretory phenotype.

Daphné Raphaëlle Vannier¹, Apeksha Shapeti^{2,3}, Florent Chuffart¹, Emmanuelle Planus¹, Sandra Manet^{1†}, Paul Rivier¹, Olivier Destaing¹, Corinne Albiges-Rizo^{1*}, Hans Van Oosterwyck^{2,3*} and Eva Faurobert^{1*⊠}.

1 Institute for Advanced Biosciences, University Grenoble Alpes, INSERM U1209, CNRS UMR5309, site santé, Allée des Alpes 38042 Grenoble, France

2 Biomechanics Section (BMe), Department of Mechanical Engineering, KU Leuven, Leuven, Belgium.

3 Prometheus, div. Skeletal Tissue Engineering, KU Leuven, Leuven, Belgium.

[†] Deceased

*Co-last authors

[™] corresponding author. E-mail for correspondance: eva.faurobert@univ-grenoble-alpes.fr

1 Abstract:

Cerebral Cavernous Malformation (CCM) is a cerebrovascular disease in which stacks of
dilated haemorrhagic capillaries form focally in the brain. Whether and how defective

- 4 mechanotransduction, cellular mosaicism and inflammation interplay to sustain the progression
- 5 of CCM disease is unknown. Here, we reveal that CCM1- and CCM2-silenced endothelial cells
- expanded *in vitro* enter into senescence-associated secretory phenotype (SASP) that they use
 to invade the extracellular matrix and attract surrounding wild-type endothelial and immune
- cells. Further, we demonstrate that this SASP is driven by the cytoskeletal, molecular and
- 9 transcriptomic disorders provoked by ROCKs dysfunctions. By this, we propose that CCM2
- and ROCKs could be parts of a scaffold controlling senescence, bringing new insights into the
- 11 emerging field of the control of aging by cellular mechanics. These *in vitro* findings reconcile
- 12 the known dysregulated traits of CCM2-deficient endothelial cells into a unique endothelial
- 13 fate. Based on these *in vitro* results, we propose that a SASP could link the increased ROCK-
- 14 dependent cell contractility in CCM2-deficient ECs with microenvironment remodelling and
- 15 long-range chemo-attraction of endothelial and immune cells.

16

17

18

19 Introduction:

- 20 Cerebral Cavernous malformations (CCM) are stacks of overgrown, dilated and haemorrhagic
- venous capillaries formed by a unique layer of poorly joined endothelial cells (ECs) without
- 22 intervening cerebral mural cells(1). Loss-of-function mutations on 3 genes (CCM1/KRIT,
- 23 *CCM2*/Malcavernin, *CCM3*/*PDCD10*) are associated with the familial form of the disease(2,3).
- 24 *CCM1* or *CCM2*-associated disease develops later in life than *CCM3* which is a more aggressive
- $25 \quad \text{form of the disease}(4,5).$
- CCM lesions expand with time and they become infiltrated by immune cells that sustain a 26 chronic inflammatory response(6,7). Intriguingly, CCM lesions are composed of a mosaic of 27 mutant and wild-type ECs (8-11). Malinverno and colleagues have further shown that the 28 29 majority of ECs bordering large mature ccm3 caverns are actually wild-type ECs that have been attracted to the lesion site at least in part by mutant ECs(11). Other studies have reported that 30 31 CCM mutant ECs secrete metalloproteases(12–14) or cytokines(15), over-produce ROS(16), present defective autophagy(17) or that they undergo an endothelial to mesenchymal transition 32 (EndMT)(18). Moreover, loss of CCM proteins activates β1 integrin (19,20), p38 MAPK(21), 33
- 34 ERK5-KLF2/4(20,22,23) and TLR4 signaling pathways(24). However, how these various
- 35 dysregulations interplay to generate CCM lesions is not well known.
- 36 A remarkable feature of CCM lesions is their peculiar mechanical microenvironment. Indeed, ECs in CCM lesions experience disturbed forces coming from stagnant blood flow(25) on their 37 luminal side and increased ECM stiffness upon matrix remodelling on their basal side(19). 38 Increased RhoA/ROCK-dependent intracellular tension (19) is a conserved feature of CCM 39 40 mutant ECs in humans and animal models (13,26-28). ROCK overactivation stimulates the polymerization of a contractile acto-myosin cytoskeleton that shifts the tensional homeostasis 41 between cell-cell and cell-extracellular matrix (ECM) adhesions. We previously showed that 42 the endothelial tensional homeostasis is actually under the control of the coupled activities of 43 the two ROCK isoforms(29). The molecular scaffold formed by the association of CCM1 and 44 45 CCM2 recruits ROCK2 to VE-cadherin complexes to promote the polymerization of a cortical acto-myosin cytoskeleton supporting cell-cell junctions. At the same time, this CCM/ROCK2 46 complex keeps ROCK1 kinase activity low thereby limiting the adhesion of the cell to the ECM. 47 When the CCM1/2 complex is lost, ROCK2 delocalizes from VE-cadherin while ROCK1 gets 48 over activated and promotes the polymerization of numerous β 1 integrin-anchored acto-myosin 49 stress fibers that most likely tear the cell-cell junctions apart(29). Importantly, it is yet unknown 50 whether, beyond their role on the architecture of the endothelium, ROCKs are also involved in 51 52 the control of gene expression downstream of CCM2.
- The mechanical defects play a primary role in the development of the disease. Inhibition of both ROCKs with chemical inhibitors, among which fasudil, blocks the genesis and maturation of CCM lesions in animal models(30–32). However, the toxicity of these drugs precludes their use in patients. It is therefore critical to find new therapies targeting specific downstream pathways. Toward this goal, we need to find a mechanistic explanation that could integrate all the different dysregulated traits of *CCM* mutant ECs.

Here, we reveal that the transcriptome of CCM2-silenced ECs cultured in vitro presents a 59 signature of Senescence-Associated Secretory Phenotype (SASP). Cellular senescence 60 contributes to a wide variety of human age-related pathologies, including cancer, fibrosis, 61 62 cardiovascular diseases, or neurological disorders(33). We demonstrate that CCM2-silenced ECs indeed enter into premature senescence and acquire degradative and invasive skills. 63 Moreover, CCM2-deficient ECs gain paracrine functions through secreted factors that are able 64 65 to attract in vitro wild-type ECs and immune cells. Remarkably, we show that this SASP is a triggered by dysfunctional ROCK1 and ROCK2 and by increased ECs contractility. This 66 unexpected endothelial fate transition triggered by the loss of CCM2 reconciles all the known 67 dysregulated features of CCM2-deficient ECs. These features, if conserved in vivo, could 68 69 support the mosaicism of the CCM lesions and their inflammatory state. 70

71

72 **Results:**

1) The loss of CCM2 turns on a SASP transcriptomic program in endothelial cells.

74 KRIT and CCM2 proteins interact with each other to form a molecular scaffold(34). We previously showed that, owing to the stabilizing effect of CCM2 on KRIT, both proteins are 75 lost when CCM2 is silenced(19). We therefore chose to silence CCM2 in order to deplete the 76 entire KRIT/CCM2 complex. To study the gene expression program of a pure population of 77 ECs depleted for CCM2, we performed RNA sequencing on monolayers of human umbilical 78 vein endothelial cells (HUVECs) after two consecutive rounds of transfection with CCM2 79 targeting siRNA (siCCM2) or with non-targeting siRNA (siNT). CCM2 silencing was of 86% 80 (figS1A) as reported in Lisowska et al., 2018(29). A total number of 2057 differentially 81 82 expressed genes (DEGs) (fold change [FC] ≥ 2 ; P < 0.05, FDR corrected using Benjamini Horchberg method (35)) were identified in siCCM2-treated compared to siNT-treated 83 HUVECs. Among these DEGs, 1316 upregulated while 739 were downregulated (Table S1). 84

85

To investigate the cellular functions altered by the loss of CCM2, we performed a Gene 86 Ontology analysis on these DEGs using cellular component (Fig 1A) and biological process 87 (Fig 1B) annotations (Table S2). Up-regulated genes were associated with the plasma 88 membrane, secretory vesicles, extracellular matrix and focal adhesions (Fig 1A). They related 89 to ECM organization, cell adhesion and migration, secretion, inflammatory response to 90 cytokines and calcium homeostasis (Fig1B). Down-regulated genes were associated with the 91 nuclear part of the cell, chromosomes, chromatin, the mitotic spindle pole, kinetochores and 92 93 microtubules (Fig 1A). They relate to DNA replication, recombination and repair, chromosome 94 segregation, microtubule-dependent movements and cell cycle progression (Fig 1B). A schematic representation of the enriched pathways found by a Reactome analysis in siCCM2 95 HUVEC is given in Figure 1C. In fact, these upregulated and downregulated functions (Fig 1B, 96 C) evoke a striking unique cellular state; a senescence-associated secretory phenotype (SASP). 97 This phenotype defines the ability of cell-cycle-arrested cells to secrete pro-inflammatory 98 cytokines, chemokines, growth factors and proteases giving rise to ECM remodelling and to the 99 stimulation of neighbour cells proliferation and invasiveness(36). 100

101

102 To test the hypothesis that a SASP transcriptomic program is turned on in siCCM2 HUVECs, we searched for specific transcriptomic signatures of senescence and SASP in the literature 103 corresponding to gene sets enriched in senescent cells among which fibroblasts and endothelial 104 cells(37-40). These gene sets relate to up- and down-regulated genes (Table S3). We then 105 106 searched for an enrichment in these gene sets in the CCM2-depleted ECs transcriptome using Gene Set Enrichment Analysis (GSEA). We confirmed that these premature replicative 107 senescence and SASP signatures are significantly enriched in the CCM2-silenced transcriptome 108 (Fig1D, Fig S2). Overall, these functional analyses of the transcriptome suggest that ECs 109 undergo a SASP when CCM2 is lost. 110

111 2) CCM2- and KRIT-depleted ECs display hallmarks of SASP.

Since a SASP transcriptomic program is turned on upon the loss of CCM2, we next sought for 112 features of premature senescence in these cells. We looked for different hallmarks, as the 113 combination of multiple traits is required to ascertain senescence(41). HUVECs were analysed 114 at passage 4 when siNT cells are still proliferative and healthy. In addition to flattening and 115 elongating upon the production of transversal stress fibers (Fig S5B), CCM2-depleted ECs 116 117 expressed almost a 3-fold increase in lysosomal senescence-associated β-galactosidase (SA-β-118 gal) activity, the historical marker of senescence (Fig 2A, 2B). In addition, their nuclei displayed senescence-associated heterochromatin foci (SAHF) as revealed by spots in DAPI 119 and HIRA staining (Fig 2C, 2D) and their area was increased (Fig 2E). As senescence leads to 120 cell cycle arrest, we looked at the expression level of the cell cycle inhibitors CDKNs. Among 121 122 them, p21/CIP1 and p15/INK4b were 3-fold upregulated (Fig 2F). On the contrary, cyclindependent kinase 1 (CDK1), its regulator CKS1B and cyclin 2A (CCN2A) as well as the 123 transcription factor E2F1, a driver of S phase entry, were all dramatically downregulated (Fig 124 S3). Using BrdU incorporation followed by cytometry analysis, we detected a 2-fold reduction 125 126 in the percentage of cells in S phase and an accumulation in G1 indicative of a defect in the G1/S transition of the cell cycle (Fig 2G). This translated into a significantly lowered rate of 127 proliferation of the ECs population as shown by impedance measurements (Fig 2H), and a two-128 fold lowered percentage of cells positive for the proliferative marker Ki67 (Fig 2I, 2J). Overall, 129 130 the combination of all these traits confirms that the loss of CCM2 indeed induced premature senescence in HUVECs. 131

Senescent cells secrete paracrine factors that can promote tumor development *in vivo* by engaging deleterious inflammatory responses and malignant phenotypes such as proliferation and invasiveness (42). We found that si*CCM2* treated HUVECs overexpressed ECM remodelling mediators including matrix proteins, metalloproteases of the MMP and ADAM families, the plasminogen activator uPA and cross-linking enzymes (Fig 2K). Moreover, they overexpress cytokines and inflammatory chemokines among which IL-1A and B, IL8, CXCL1, 2, CCL20 and EREG that are hallmarks of SASP (43) (Fig 2K).

Having shown that the loss of CCM2 leads to SASP in HUVECs, we wondered whether this 139 would also be conserved in cerebral microvascular ECs (HBMVECs), an in vitro cellular model 140 more closely related to CCM. We also wondered whether this SASP would be a common 141 feature of ECs depleted for KRIT and CCM3. Therefore, each of these proteins was depleted 142 in HUVECs and HBMVECs (Fig S1B) and the appearance of marks of senescence was 143 analysed. Firstly, results in HBMVECs paralleled that in HUVECs (Fig 3) confirming that the 144 loss of CCM2 also led to senescence in brain microvascular ECs. Moreover, KRIT-depleted 145 146 HUVECs or HBMVECs displayed the same senescent phenotype as CCM2-depleted HUVECs or HBVMECs. We observed an increase in cells expressing SA-β-gal activity (Fig 3A-D) and 147 148 HIRA nuclear foci (Fig 3E-H), and a decrease in Ki67-positive cells (Fig 3I-L). Morover, their proliferation rate was consistently reduced (Fig 3M-N). Interestingly, CCM3-depleted 149 HUVECs or HBMVECs did not display marks of senescence and behaved as control cells in 150 these assays in good agreement with CCM3 distinct role in ECs biology and onset of the 151 disease(44). They did not show increased SA-βgal activity (Fig 3A-D), nor HIRA nuclear foci 152 (Fig 3E-H). They had a normal level of Ki67 positive cells (Fig 3I-L) and they did not 153

- 154 proliferate differently from control cells (Fig 3M-N). Therefore, consistently with their strong
- association and regulation of common signaling pathways (19,44), the loss of KRIT and CCM2
- similarly lead to premature *in vitro* cellular senescence of brain microvascular ECs.

157 3) ROCK2 controls the SASP transcriptomic program of CCM2-depleted ECs

158 ROCK-dependent perturbations in the mechanotransduction of ECs have a major role in the genesis and progression of CCM lesions. Inhibition of ROCK is sufficient to block the 159 formation and the maturation of CCM lesions (30-32). We previously showed that the CCM1/2 160 complex is a scaffold recruiting ROCK2 at VE-cadherin complexes thereby limiting ROCK1 161 kinase activity to maintain the tensional homeostasis between cell-cell and cell-ECM adhesions. 162 This coordination between ROCK1 and ROCK2 activities preserve the integrity of the 163 endothelial monolayer(29). However, it is yet unknown whether ROCKs are also involved in 164 the control of gene expression downstream of CCM2 and in particular in the regulation of this 165 SASP transcriptomic program. Hence, we analysed the contribution of ROCK1 and ROCK2 by 166 167 performing RNA sequencing on monolayers of CCM2-silenced HUVECs that were additionally silenced for ROCK1 or ROCK2 or HUVECs silenced only for ROCK1 or ROCK2 168 (Fig S1A) in the same set of experiments as that shown in figure 1. We have previously shown 169 that the additional depletion of ROCK1 but not ROCK2 restores the morphological defects of 170 the CCM2-deficient HUVECs and their permeability barrier(29). Similar phenotypes were 171 observed in HBMVECs (Fig S5A). Strikingly, 65% of the DEGs with log2FC>1 had their 172 expression significantly returned toward the control level by the additional silencing of ROCKs 173 (Fig 4A, Table S4). The silencing of ROCK2 had a stronger restoring effect than that of ROCK1 174 175 on the number of restored genes (Fig 4A, Table S4) and their level of expression (Fig 4B). Importantly, silencing of ROCK2 alone had overall an opposite effect to that of CCM2 on gene 176 expression (Fig 4B), suggesting that ROCK2 acquires a gain of transcriptional function when 177 CCM2 is lost. 178

We then studied the restoring effect of ROCK1 or ROCK2 silencing on the biological functions 179 perturbed by CCM2 depletion. Table S5 gives the Gene Ontology analysis of the biological 180 181 functions of the DEGs restored by ROCK1 and ROCK2 (common DEGs) or restored specifically by ROCK1 or ROCK2. ROCK2 had a broad restoring effect on all the biological 182 functions dysregulated upon the loss of CCM2. Figure 4C shows the heatmap of the expression 183 of DEGs associated with GO biological processes found enriched in siCCM2 cells. The 184 expression of DEGs related to the down-regulated nuclear functions in siCCM2 HUVECs was 185 fully restored by ROCK2 depletion while ROCK1 depletion had only a partial effect. In 186 addition, up-regulated peri-membrane functions were rescued by the silencing of ROCK2 to a 187 higher extent than that of ROCK1 (Fig 4C). Going further, we focused on the effect of ROCKs 188 on the signatures of senescence or SASP found in siCCM2 transcriptome. While these 189 signatures of senescence were still present upon ROCK1 depletion, they were not anymore 190 significantly enriched in HUVECs doubly silenced for CCM2 and ROCK2 (Fig 4D, Fig S2). 191

Overall, our transcriptomic data reveal that, beyond their role on the cytoskeletal homeostasisof the endothelial monolayer, ROCK2 and to a lesser extent ROCK1 has a massive effect on

the genes regulated by CCM2. These genes are involved in a transcriptomic program supporting

the onset of SASP when CCM2 is lost.

196 4) ROCKs dysfunctions induce premature senescence in CCM2-depleted ECs.

Having shown that ROCKs mediate the expression of genes involved in SASP, we next asked 197 whether dysfunctional ROCKs played a causal role in the entry into SASP of CCM2-depleted 198 ECs. Additional silencing of ROCK1 or ROCK2 in HUVECs and HBMVECs was similarly 199 efficient in preventing the appearance of most of the features of senescence tested i.e. SA-β-gal 200 activity, HIRA-positive SAHF and restored normal level of Ki67+ cells (Fig 5A, B, C, F, Fig 201 S6). However, ROCK2 silencing was more efficient in preventing the accumulation of 202 HUVECs in the G1 phase of the cell cycle (Fig 5E). This effect of ROCK2 silencing is 203 204 consistent with its higher efficiency in lowering the expression of p21/CIP1 and p15/INK4b (Fig 5D) and in restoring the gene expression of down-regulated cyclins and cyclin dependent 205 kinases (Fig S3). Moreover, the silencing of ROCK2 and to a lesser extent that of ROCK1 206 207 lowered the expression of SASP factors, i.e. ECM remodelers or inflammatory chemokines (Fig 5G, H). 208

- Our next goal was then to know whether the cytoskeletal defects provoked by dysregulated 209 ROCK1 and ROCK2 play a direct role in the premature senescence of CCM2-depleted 210 211 HUVECs. To answer this question, we treated siCCM2 HUVECs with blebbistatin, an inhibitor of myosin II that blocks cell contractility or with Y-27632, an inhibitor of ROCK1 and 2 kinase 212 activities. Both treatments inhibited the production of transversal actin stress fibers found in 213 siCCM2 HUVECs and siCCM2 HBMVECs and restored a more cortical actin rim alike the one 214 215 observed in control HUVECs (Fig S5A, B). Interestingly, these treatments inhibited all the senescent traits studied above, i.e. high SA-β-gal activity, HIRA-positive SAHF and 216 accumulation in G1 phase of the cell cycle and restored normal level of Ki67+ cells (Fig 5A, 217 B, C, E, F; Fig S6). These results support the fact that increased contractility is involved in the 218 premature senescence of CCM2-depleted ECs. Noticeably, blebbistatin and Y-27632 had no 219
- effect on siNT HUVECs in these assays (Fig S5C, D, and E).
- Overall, these data reveal that dysregulated ROCK1 and ROCK2 functions together with increased cell contractility lead CCM2-depleted ECs to enter into a premature senescence.
- 223

S) ROCK1 mediates ECM degradation and supports invasiveness of CCM2-depleted ECs and neighbouring WT ECs.

226 Cancer cells undergoing SASP can promote tumour development through a juxtacrine effect on 227 their microenvironment by secreting matrix metalloproteinases (MMPs) and ECM remodeling enzymes that facilitate tumour cell invasiveness and metastasis(42). Similar to cancer 228 progression, the formation of CCM lesions could result from a SASP-dependent invasion of the 229 brain tissue by ECs. Consistently, MMPs have been found around CCM lesions in human(14) 230 231 and in mouse(13), or zebrafish models(22) and their upregulation plays a role in CCM defects (12,20). To know whether upregulated expression of SASP factors confers invasive skills to 232 siCCM2 HUVECs, we tested the ability of these cells to degrade ECM and invade a 3D matrix. 233 To visualize the degradation of the ECM, siRNA transfected HUVECs or HBMVECs were 234

cultured overnight on fluorescent gelatin. siNT ECs barely degraded the gelatin as expected for 235 differentiated ECs (Fig 6A, B; Fig S7A, B). Conversely and consistently with their new SASP 236 expression program, siCCM2 ECs degraded the gelatin through scratch zones appearing dark 237 in the fluorescently labelled layer (Fig 6A; FigS7A). The linear shapes of these scratch zones 238 suggested that they were produced under focal adhesions. They were dependent on the activity 239 of MMPs as demonstrated by their complete disappearance upon MMP inhibitor GM-6001 240 241 treatment (Fig 6A, B). Together with blocking the mechanosensitive assembly of focal adhesions (Fig S5F), Y-27632 and blebbistatin blocked the degradation of gelatin (Fig 6A, B; 242 Fig S7A, B). We previously showed that additional silencing of ROCK1, but not of ROCK2, 243 limits excessive focal adhesion formation in siCCM2 ECs(29). Accordingly, only the additional 244 depletion of ROCK1 inhibited ECM degradation by siCCM2 ECs (Fig 6A, B; Fig S7). Overall, 245 these data show that ROCK1-dependent increase in cell contractility and in cell-ECM adhesive 246 sites together with the overexpression of MMPs are responsible for the acquisition of ECM 247 degradative skills by siCCM2 ECs. 248

We next tested whether these senescent ECs had acquired invasive skills. Consistently with 249 Maddaluno et al. (18), these cells expressed mesenchymal markers suggestive of an invasive 250 phenotype (Fig S8). Interestingly, the expression of the EndMT markers were returned toward 251 siNT level by the additional silencing of ROCKs (Fig S8). To actually measure their 3D 252 invasiveness, GFP-expressing siRNA treated HUVECs were plated on 3D-degradable 253 polyethylene glycol gels (PEG). Invasive sprouts were imaged after 18 hours and the maximum 254 255 invasion distance was quantified. siCCM2 HUVECs invaded the 3D gel twice as deep as siNT HUVECs (Fig 6D). Moreover, upon silencing of CCM2, the leading cells consistently detached 256 from the multicellular sprouts and migrated independently (Fig 6C). Additional silencing of 257 258 ROCK1 or blebbistatin treatment reduced the invasiveness of siCCM2 HUVECs to the level of siNT HUVECs and blocked the detachment of the leading EC whereas silencing of ROCK2 259 enhanced them (Fig 6C, D). This promotion of invasiveness upon ROCK2 additional depletion 260 is consistent with their increased traction forces recorded in a previous work(29). 261

262

263 CCM lesions are mosaics of mutant and WT ECs as shown in human and murine lesions(9-11). Moreover, it has been shown that CCM3 KO ECs can attract WT ECs in vivo in the brain 264 vasculature and *in vitro* on mixed monolayers(11). Therefore, we asked whether senescent 265 siCCM2 HUVECs could also stimulate the sprouting of WT HUVECs when mixed together on 266 the surface of 3D-PEG gels. Strikingly, we observed that RFP-expressing WT HUVECs 267 invaded the gels twice as deep when they were mixed with GFP-expressing siCCM2 HUVECs 268 as when mixed with GFP-expressing siNT HUVECs (Fig 6E, F). Interestingly, this increased 269 invasion was significantly reduced when WT HUVECs were mixed with siCCM2+siROCK1 270 HUVECs but remained unchanged when they were mixed with siCCM2+siROCK2 HUVECs 271 272 (Fig 6E, F).

Altogether, our results show that senescent si*CCM2* HUVECs have acquired a ROCK1dependent capacity to invade the ECM and to sustain the invasion by WT HUVECs.

275

6) ROCK2 mediates the expression of paracrine factors by CCM2-depleted ECs that chemo-attract WT ECs and immune cells.

Apart from remodelling their surrounding ECM, senescent cells secrete paracrine factors that 278 have been shown to promote invasiveness of neighbouring cells and engage deleterious 279 inflammatory responses (42). A chronic inflammation is observed at the site of human and 280 murine CCM lesions through the recruitment of activated lymphocytes and monocytes(45). Our 281 transcriptome analysis showed the upregulation of around 30 cytokines upon CCM2 loss that 282 283 returned towards control level by ROCKs silencing (Fig 5H). These inflammatory cytokines have a broad spectrum of targets among immune cells and ECs and bear different roles on cell 284 proliferation, differentiation and chemoattraction as summarized in table S6. 285

We first tested whether these secreted factors would have a long distance paracrine effect 286 allowing the recruitment of WT ECs. We measured the capacity of a media conditioned by 287 siCCM2 HUVECs to chemo-attract serum-starved WT HUVECs through a layer of Matrigel in 288 289 a modified Boyden chamber measuring the impedance of cells. Remarkably, siCCM2conditioned media significantly increased the speed of invasion of WT HUVECs through the 290 Matrigel showing that chemo-attractive factors secreted by siCCM2 HUVECs could also attract 291 ECs (Fig 6G). Interestingly, this effect was inhibited by ROCK2 but not ROCK1 additional 292 293 silencing (Fig 6G). Therefore, siCCM2 HUVECs produce paracrine factors that attract WT ECs in a ROCK2-dependent manner. 294

We then tested whether the loss of CCM2 leads to the secretion of chemo-attractive cues for 295 immune cells. Thus, we measured the capacity of media conditioned by siCCM2 HUVECs or 296 HBMVECs to chemo-attract IMAC, an immortalized macrophage cell line in a modified 297 Boyden chamber as above. Almost no transmigration of macrophages was observed in the case 298 299 of siNT-conditioned media (Fig 6H; Fig S7C). Strikingly, siCCM2-conditioned media provoked a rapid transmigration of the macrophages suggesting that siCCM2 ECs had secreted 300 chemo-attractive factors that siNT HUVECs had not (Fig 6H; Fig S7C). Importantly, this 301 chemo-attraction was inhibited when ROCK2 but not ROCK1 was additionally silenced (Fig 302 303 6H; Fig S7C). Therefore, siCCM2 ECs secrete paracrine factors that can attract immune cells such as macrophages. Moreover, these chemo-attraction skills depend on ROCK2. 304

Overall, these results demonstrate for the first time to our knowledge that, when CCM2 is lost,
 ECs cultured *in vitro* undergo a SASP that is driven by the cytoskeketal and molecular disorders
 provoked by ROCKs dysfunctions. A major consequence of this SASP is a profound ROCKs dependent remodelling of the microenvironment leading to the recruitment of wild-type ECs
 and immune cells.

310 Discussion

Many cellular pathways are dysregulated in CCM-deficient ECs and it has been difficult to 311 propose a mechanistic model that could take into account all these aspects. In these cells, 312 transition in cellular fate(18) upon morphological and cytoskeletal changes during the loss of 313 cell-cell junctions(19,29,46) are associated with overproduction of ROS(16), decreased 314 autophagy(17), secretion of metalloproteases(12-14) or cytokines(15) and increased 315 integrin(19,20), p38(21), MEKK3/KLF2(20,22,23) and TLR4(24) signaling. The first 316 317 breakthrough of this current study is to show, for the first time to our knowledge, that CCM2deficient ECs engage *in vitro* towards a Senescence-Associated Secretory Phenotype (SASP) 318 (Fig 7). Multiple senescent traits were validated such as a transcriptomic SASP signature (Fig 319 1D), high lysosomal SA-β-galactosidase activity, an upregulation of CDK inhibitors, a cell 320 cycle blockage in G1 phase, the presence of SAHF along with the secretion of chemo-attractant 321 factors (Fig 2). Moreover, we show that the functional consequence of this SASP is an acquired 322 ability of CCM2-deficient ECs to invade the ECM and recruit wild-type ECs and immune cells 323 324 (Fig 6 G-H). Whereas the absence of *in vivo* data is a limitation to our work, our studies on pure 325 and mixed populations of CCM2-depleted and WT ECs have brought up new hypotheses on the mechanisms underlying the mosaicism of the CCM lesions by proposing the juxtacrine (Fig 326 6E) and paracrine (Fig 6F, G) attraction of WT ECs and immune cells by mutant ECs. These 327 328 hypotheses will have to be tested in vivo.

329

The SASP is characterized by cell growth arrest, widespread changes in chromatin organization 330 and gene expression(36). These changes also include the secretion of numerous pro-331 inflammatory cytokines, chemokines, growth factors and proteases(43). Acute senescence is 332 beneficial in development, tissue regeneration or cancer through the clearance of senescent cells 333 by the immune system(47). Chronic senescence triggers chronic inflammation that can on the 334 contrary favour age-related diseases including cancer, fibrosis, cardiovascular diseases, type 2 335 diabetes, osteoarthritis or neurological disorders(33). Indeed, the long-term secreted pro-336 inflammatory factors promote cell proliferation, microenvironment remodelling, angiogenesis 337 and inflammation in a paracrine manner. Remarkably, decreased autophagy(48), ROS 338 overproduction(49), P38 MAPK(50), KLF2/4(51,52) and TLR4(53) signaling pathways have 339 all been involved in the induction of the SASP either through regulation of CDK inhibitors or 340 through the NFkB or C/EBPβ-driven expression of cytokines. Therefore, we propose that each 341 of the dysregulated features of CCM-deficient ECs represents a different facet of the same 342 cellular state. Future research should help reconstructing the complex chronology of the 343 different events in the framework of this SASP. This could help identifying key therapeutic 344 targets for either single or combinatorial drug treatments to block at their root the defective 345 molecular pathways involved in the CCM2 disease. Senolytic drugs and drugs targeting the 346 SASP per se are currently under pre-clinicial trials for cancer therapy or other age-related 347 diseases(33). They could be tested to prevent the formation and expansion of CCM lesions. A 348 349 recent study strongly supports that premature aging of the neurovascular system could be the cause of CCM disease by showing that aging and CCM brains share common dysregulated 350 features including impaired endothelial barrier function, inflammation, 320 DEGs, plasma 351 molecules and imaging biomarkers (54). 352

354 A third hit corresponding to an oncogenic mutation on PI3K was recently detected in human CCM lesions that adds to the somatic loss-of-function mutation on the CCM genes (55). 355 Interestingly, cellular senescence is a well-known response to oncogenic stress which arrests 356 the aberrant proliferation of the cancerous cell(36). The expansion of ECs through several 357 358 passages in our *in vitro* experiments may have mimicked the oncogenic stress occurring *in vivo*. 359 Importantly, it has allowed the discovery of the increased sensitivity of KRIT- and CCM2depleted ECs to senescence. Differently from KRIT and CCM2, the loss of CCM3 was actually 360 shown to preserve primary ECs from replicative senescence *in vitro*(56). We found that CCM3 361 depletion does not at least increase the sensitivity of the ECs to replicative senescence (Fig 3). 362 These differences in sensitivity to senescence may explain the different time courses of CCM 363 diseases. Premature senescence of KRIT- or CCM2-deficient ECs after a first phase of clonal 364 proliferation may lead to the progressive maturation of lesions through recruitment of WT ECs 365 and to the late onset of the CCM1/2 disease. Differently, a more prolonged phase of clonal 366 367 proliferation of CCM3-deficient ECs may trigger the formation of aggressive lesions at early age. Using the confetti reporter system in Ccm1/2 mouse models made compatible with SA-β-368 369 galactosidase staining would help testing the occurrence of a SASP in vivo, its time course and allow the comparison with the Ccm3 model. 370

371

353

The second major breakthrough of this study is that dysregulated ROCKs are involved in the 372 onset of this SASP in our in vitro endothelial models. The fact that cellular mechanical defects 373 can provoke senescence is an emerging area of investigations(57). We previously showed that 374 upon the loss of CCM1/2, a vicious cycle sets up between aberrant ECM remodelling and 375 increased intracellular contractility which breaks the permeability barrier of the 376 endothelium(19). Moreover, we demonstrated that placing WT ECs on ECM remodelled by 377 378 mutant ECs provoke CCM-like morphological defects in these cells(19). Going deeper into 379 mechanistic investigations, we showed that upon the loss of CCM2, ROCK2 is delocalized 380 from VE-cadherin junctions while ROCK1 gets over activated, enhancing the polymerization of $\beta 1$ integrin-anchored stress fibers(29). Here we uncover for the first time that, beyond their 381 382 role in the disruption of the endothelial monolayer architecture, dysregulated ROCKs are instrumental in the *in vitro* transition of CCM2-depleted ECs towards a SASP (Fig 7). 383

384

ROCK2 controls the expression of a very significant fraction of the genes dysregulated upon 385 386 the loss of CCM2 among which genes involved in senescence, cell cycle and paracrine SASP factors. The tendency to opposite expression profiles in absence of CCM2 or ROCK2 suggests 387 that ROCK2 could gain a broad transcriptional regulatory function when its scaffold CCM2 is 388 lost (Fig 4B). In fact, ROCK2 has already been involved in cellular senescence(58). In this 389 study, the loss of the two ROCK isoforms led to senescence of MEF and was due to the 390 downregulation of CDK1, CKS1 and cyclin2A. Intriguingly, we observe a similar 391 downregulation of these genes in HUVECs when CCM2 is lost (Fig S3), but contrary to this 392 other study, their expression is rescued by the additional silencing of ROCK2. This suggests 393 that the presence or absence of CCM2 has could have a strong influence on the transcriptional 394 activity of ROCK2. KRIT is found at cell-cell junctions and shuttles between the cytoplasm 395 and the nucleus(59,60). We previously showed that it acts as a scaffold to recruit ROCK2 at 396

VE-cadherin dependent-Adherens junctions(29). ROCK2 has also been shown to translocate to
the nucleus(61,62). It is therefore possible that KRIT and ROCK2 shuttle together and that
KRIT loss impairs ROCK2 nuclear localization. Future mechanistic studies will be necessary
to understand whether and how ROCKs interplay with the CCM complex to modulate ROCK2
nucleocytoplasmic shuttling and its regulatory functions on gene expression.

402

403 We previously showed that ROCK1 overactivation allows CCM2-depleted HUVECs to exert stronger traction forces on the ECM (19,29). Here we show that ROCK1 enables the 404 mechanosensitive degradation and invasion of the ECM by the senescent CCM2-depleted ECs 405 and by neighbouring WT ECs. Since ECs pull on their microenvironment to invade it(63), it is 406 likely that these stronger forces are responsible for enhanced invasion. Further investigations 407 will help to better understand the molecular events at play. Like ROCK2, ROCK1 affects gene 408 expression downstream of CCM2 though to a lesser extent. Moreover, inhibition of the myosin 409 motor or silencing of ROCK1 is enough to block senescence. These data suggest that cross talks 410 411 may exist between the contractility of the acto-myosin cytoskeleton and the transcription of genes involved in SASP. Indeed, mechanosensitive transcription factors and/or epigenetic 412 factors could have their activity affected by the CCM/ROCKs-dependent increase in acto-413 myosin contractility. As such, it is known that F-actin polymerization controls the shuttling of 414 MRTF to the nucleus and that ROCK2 is required for YAP nuclear localization (64,65). 415 Moreover, ROCK2 binds to and phosphorylates p300 increasing its acetyltransferase 416 activity(61). The mechanosensitive transcription factors KLF2 and KLF4 have a causative role 417 in the pathogenesis of the CCM disease(13,20,23). Intriguingly, KLF2/4 transcriptional 418 activities are modified by acetylation by p300(66,67) and the anti-inflammatory function of 419 420 KLF2 requires p300(66). The regulation of p300 by ROCK2 may control in turn KLF2/4 antiinflammatory activities. Future investigations should unravel how ROCK1 and ROCK2 421 cooperate to regulate chromatin organization and gene expression through the control of 422 mechanosensitive transcription machineries. 423

424

Overall, this study demonstrates that CCM2-deficient ECs undergo a SASP in vitro that is 425 driven by the cytoskeletal, transcriptional and molecular disorders provoked by ROCKs 426 dysfunctions. Remarkably, this discovery unifies all the known dysregulated traits of CCM1/2-427 428 deficient ECs into a unique cellular state that could, if validated in vivo, trigger the remodelling 429 of a microenvironment favourable for the chronic recruitment of wild-type ECs and immune cells to the site of the lesion. These in vitro observations open new avenues for mechanistic in 430 vivo studies on the dynamics and penetrance of the CCM disease as well as for exploring new 431 therapies. 432

433 Material and Methods

434 Cell culture and transfections:

Pooled HUVECs (human umbilical vein endothelial cells) and HBMVECs (human brain 435 microvascular endothelial cells) were obtained from Lonza and Pelobiotech respectively. Upon 436 reception, HUVECs at passage 0 and HBMVECs at passage 2 were expanded over 2 and 1 437 passage respectively in collagen 1 (from rat tail, BD) coated flasks in complete EGM-2 medium 438 (HUVECs) or EGM-2MV (HBMVECs) supplemented with 100 U/ml penicillin and 100 ug/ml 439 streptomycin at 37°C in a 5% CO₂ - 3% O₂ humidified chamber. Cells were transfected twice 440 at 24 h-interval with 30 nM siRNA and Lipofectamine RNAi max (Life Technologies, ref. 441 13778-150) according to the manufacturer's instructions in 37°C in a regular 5% CO₂ in a 442 443 humidified chamber. For double transfections, 30 nM of each siRNA duplexes (Dharmacon smartpool ON-TARGET plus Thermo Scientific) was used; Non-targeting siRNA #1, CCM2; 444 445 ref. L-014728-01), KRIT; ref. L-003825-00, CCM3; ref. L-004436-00, ROCK1; ref. L-003536-446 00 and ROCK2; ref. L-004610-00. When required, Blebbistatin, Y-27632 and GM6001 were used at 10 µM final. IMAC (SV40 immortalized mouse bone marrow derived macrophages, 447 gift from B. Py, CIRI, Lyon) were cultured in DMEM supplemented with 10% foetal calf 448 serum, 100 U/ml penicillin and 100 μ g/ml streptomycin at 37°C in a 5% CO₂. 449

450 **RNA sequencing and differential analysis:**

One million of siRNA transfected HUVECs were seeded at confluence the day after the second 451 452 round of transfection in wells of 6-well plates coated with collagen 1 (from rat tail, BD) and cultured for 48h in complete media at 37°C, 5% CO2. Three independent experiments were 453 performed, each with 6 experimental conditions: siNT, siCCM2, siCCM2+siROCK1, 454 siCCM2+siROCK2, siROCK1 and siROCK2. Total RNA were extracted from HUVECs using 455 456 the NucleoSpin RNA II kit (Macherey-Nagel) according to the manufacturer's instructions. cDNA libraries were prepared with the TruSeq Stranded mRNA Sample Preparation (Illumina) 457 and sequenced on a HiSeq 2500 Illumina platform using single-end 50 basepair reads at the 458 MGX facility (Montpellier). Fastq files were aligned using STAR (2.5.2b) on UCSC hg19 459 460 genome. The contents of the annotation directories were downloaded from UCSC on: July 17, 2015. Bam files were counted using htseq-count (0.11.2.) with option -t exon -f bam -r pos -s 461 reverse -m intersection-strict -nonunique none. Differential analyses were performed with 462 SARTools (1.4.1) (68) using DESeq2 (1.12.3) (69) and default options. P-values were adjusted 463 with Benjamini-Hochberg procedure(35) set for 5% of FDR. Heatmaps using a correlation 464 matrix and boxplots were obtained with custom R script (3.3.0). The raw sequencing data used 465 in this study are available in the National Center for Biotechnology Information's Gene 466 Expression Omnibus (GEO) database and are accessible through GEO series accession number 467 (pending). 468

469

470 Data Availability: The raw data (FastQ files) and processed data (count files) are deposited in
471 the Gene Expression Omnibus database under ID code GEO: GSE165406, token
472 gnujmwcqdjohhkb (for reviewers). All data supporting the findings of this study are available
473 from the corresponding author on reasonable request.

474

475 **Bioinformatics analyses:**

476 Gene ontology analyses on DEGs in si*CCM2* condition (fold change [FC] ≥ 2 ; P < 0.05 with

477 FDR corrected using Benjamini Horchberg method (35)) were made with PANTHER version

478 15,0 Released 2020-02-14 using slim cellular components and biological processes. Enriched

- 479 pathways analyses were conducted with Reactome. DEGs (P < 0.05, 5% FDR) rescued by 480 additional silencing of ROCK1 or ROCK2 were recovered at the union of Venn diagrams of
- 481 DEGs in si*CCM2* vs siNT and DEGs in si*CCM2* vs si*CCM2*+ROCK1 or ROCK2 respectively.
- 482 Gene Set Enrichment Analyses were conducted using GSEA software from Broad Institute,
- 483 UC San Diego(70).

484 **Quantitative RT-PCR:**

Purified RNA (1 µg) were reverse transcribed using the iScript Reverse Transcription Supermix 485 (Biorad). Quantitative real-time PCR (Q-PCR) was performed with iTaq Universal SYBR 486 Green Supermix (Biorad) in a 20 µl reaction on a thermal cycler (C-1000 Touch; Bio-Rad 487 Laboratories). Product sizes were controlled by DNA gel electrophoresis and the melt curves 488 489 were evaluated using CFX Manager (Bio-Rad Laboratories). A total of three housekeeping genes were selected for their stability in HUVECs or HBMVECs under our experimental 490 conditions, using the three analytical software programs, geNorm, Normfinder and Bestkeeper 491 (71,72). We used the relative expression software tool CFX Manager for relative quantification, 492 and normalization was achieved using a normalization factor from all reference genes(71). The 493 mean of three technical replicates was calculated per biological replicate. 494

495 Immunofluorescence staining:

HUVECs or HBMVECs were seeded at $5x10^4$ cells or $2x10^5$ cells in 24-well plates on 496 coverslips coated with 10 µg/ml fibronectin (from human plasma, Sigma Aldrich) and 497 incubated overnight in complete EBM-2 medium. Cells were fixed with 4% PFA, 498 permeabilized with 0.2% Triton X-100, and incubated with anti-activated $\beta 1$ integrin clone 499 500 9EG7 ((BD Biosciences, 1/200), anti-Ki67 (AN9260 Millipore, 1/200), anti-HIRA (WC119, Millipore, 1/200) and anti β-catenin clone 8E7 (Merck, 1/2000). After rinsing, coverslips were 501 incubated in Goat anti-Mouse or anti-Rabbit IgG (H+L) highly cross-adsorbed secondary 502 antibody, Alexa Fluor conjugated AF 488, AF 546, AF 647 (Invitrogen, 1/1000) and phalloidin 503 conjugates with Atto 647 (Sigma, 1/2000). The coverslips were mounted in Mowiol/DAPI 504 solution and imaged on an epifluorescent Axiomager microscope (Zeiss) at 63X magnification. 505

506 SA-B-Galactosidase staining:

507 HUVECs or HBMVECs were seeded 48 hours after the second siRNA transfection at a density

of $5x10^4$ in 24-well plates coated with $10\mu g/mL$ fibronectin and incubated overnight in

- 509 complete EBM-2-medium. Senescence-Associated β -galactosidase activity was assessed using
- 510 a SA- β -galactosidase staining kit according to the manufacturer's instructions (Cell Signaling).
- 511 Positive cells were counted manually out of more than 100 cells total.
- 512 BrdU assay:

513 HUVECs were seeded 48 hours after the second siRNA transfection at a density of $2x10^5$ cells 514 in 6-well plates coated with 100μ g/mL collagen 1 and incubated overnight in complete EBM-515 2 medium. The BrdU assay was performed with the BD Accuri C6 flow cytometer using the 516 APC-BrdU flow kit according to the manufacturer's instructions (Cell Signaling).

C

517 xCELLigence proliferation assay:

Proliferation assay was performed using the xCELLigence Real-Time Cell Analysis (RTCA) 518 DP instrument in combination with E-plate 16 (ACEA Biosciences) coated with 100µL of 519 100µg/mL collagen 1 (from rat tail) for 30 min at 37°C and washed 2 times with PBS 1X. 40 520 µL of complete EBM-2 medium was added and baseline without cells was made with RTCA 521 522 software. SiRNA transfected HUVECs or HBMVECs were seeded at 5-10% confluence 48h 523 after the second round of transfection in 100µL of complete EBM-2-medium. Impedance measurements were recorded every 5 min during 24h. Impedance was normalized at 4 hours 524 525 after seeding to eliminate the contribution of cell spreading and adhesion to the signal. Slope 526 measurement was performed between 4h and 24h.

527 Matrigel invasion assay:

This assay was performed using the xCELLigence RTCA DP instrument in combination with 528 529 CIM-Plate 16 (ACEA Biosciences). A layer of 3.3% of growth factor reduced Matrigel 530 (Corning) diluted with EBM basal media was poured on ice in the upper chamber and incubated overnight at 37°C for polymerization. 40 µl basal EBM media was added to the upper chamber 531 532 and the baseline made after equilibration at 37° C. After setting the baseline, $3x10^{4}$ WT HUVECs were added to the upper chamber. The conditioned media from siRNA transfected 533 cells was recovered 48 h after the second round of transfection and centrifuged at 12000 rpm 534 for 5 min and 160µL was added to the lower chamber of the CIM-plate. After one hour of 535 equilibration at 37°C, impedance was measured every 3 minutes for 24 hours. 536

537 Chemo-attraction assay:

538 This assay was performed using the xCELLigence Real-Time Cell Analysis (RTCA) DP

instrument in combination with CIM-Plate 16 (ACEA Biosciences). After setting the baseline,

540 $3x10^5$ IMAC were added in 100µL of basal EBM in the upper chamber and 48h-conditioned

- 541 media from siRNA transfected HUVECs or HBMVECs added to the lower chamber of the
- 542 CIM-plate. After 30 min equilibration at 37°C, impedance was measured every 3 minutes for
- 543 24 hours.

544 Gelation degradation assay:

545 Coverslips in 24 well-plates were coated with gelatin-Alexa488 dye as previously described

546 (73). SiRNA transfected HUVECs or HBMVECs were seeded 48h after the second siRNA

transfection at 5×10^4 /well and incubated in OptiMEM medium overnight at 37° C in a 5% CO₂

incubator, fixed with 4% PFA, and washed with PBS twice. For a quantitative analysis of the

- 549 degradative skill of siRNA transfected cells, 5 images per condition were acquired over the
- entire coverslip with an epifluorescent Axiomager microscope (Zeiss) at 40X magnification, and were converted to binary images using B & W thresholding on ImageI. The total area of the
- and were converted to binary images using B&W thresholding on ImageJ. The total area of the

black zones corresponding to the total area of degradation of the fluorescent gelatin wasmeasured.

554 **3D-PEG invasion assays:**

Poly-ethylene glycol (PEG) hydrogels were prepared on ice in EBM-2 complete media by 555 combining an MMP-sensitive peptide modified PEG precursor (8-arm 40kDa,(74)) at 1.5% 556 polymer concentration, 50 µM Lys-RGD peptide (Pepmic), and 1 µM sphingosine-1-phosphate 557 (S1P, Sigma-Aldrich). The hydrogels were enzymatically crosslinked using a reconstituted and 558 thrombin-activated Factor XIII (Fibrogammin, CSL Behring), prepared as previously described 559 (75)) at 10% of total hydrogel volume. A 20 µL volume of the hydrogel suspension was pipetted 560 into a modified imaging chamber (Secure-Seal[™] hybridization sealing systems, ThermoFisher 561 Scientific) attached to the bottom of a 24-well plate held vertically (63). The hydrogel was 562 allowed to polymerize for 30 minutes in this orientation at room temperature prior to cell 563 seeding. Depending on the study, a confluent cell monolayer composed of either 5X10⁴ siRNA 564 565 transfected GFP-HUVECs or a 1:1 ratio mixture of siRNA transfected GFP-HUVECs and naïve RFP-HUVECs was allowed to adhere to the PEG meniscus at 37°C, 5% CO₂ for 1 hour and 566 then placed back horizontally with 1mL of EBM-2 complete media. Fixation with 4% PFA in 567 DPBS was performed after 24 hours. Sprouts invading the PEG hydrogel were imaged using a 568 569 Leica SP8 inverted confocal microscope with an HC PL APO 10x, 0.4 numerical aperture dry objective to obtain image stacks at 1024x1024 pixels with a 50 µm Z-stack at 1-1.5 µm Z-570 spacing. A Z-projection of each image was used to manually quantify invasion distances using 571 the line measurement tool of ImageJ. More than 100 sprouts were analyzed per technical 572 573 replicate.

574

575 **Statistical tests:**

Results were assessed by the Tukey's multiple comparison tests post-ANOVA to compare with
control; a 0.5 alpha level was used for all comparisons. Prism software was used to conduct the
statistical analysis of all data. P<0.05 was considered to be significant. *P<0.05, **P<0.05,
***P<0.005. n represents biological replicates.

580 Acknowledgements:

Most of the computations presented in this paper were performed using the CIMENT/GRICAD 581 infrastructure (https://gricad.univ-grenoble-alpes.fr). The authors acknowledge the EpiMed 582 core facility (http://epimed.univ-grenoble-alpes.fr) for their support and assistance in this work. 583 This study was supported by the ANR (ANR-17-CE13-022), the Fondation pour la Recherche 584 Médicale FRM (DEQ20170336702), the International Emerging Action CNRS, the association 585 586 Espoir contre le Cancer Isère, the FWO project G087018N, infrastructure grant I009718N, Hercules Foundation (G0H6316N), the European Research Council under the European 587 Union's Seventh Framework Program (FP7/2007-2013)/ ERC Grant Agreement No. 308223). 588 589 PhD fellowship grants were supported by ANR and FRM to D.R.V. and FWO (1S68818N) to A.S. We would like to thank Claudia Röedel, Béatrice Eymin, and Gwénola Boulday for sharing 590 ideas and reagents, Salim Seyfried for critical reading of the manuscript, and Christiane Oddou 591 for excellent technical assistance. 592

593 Author contributions

594

D.R.V., A.S., H.V.O., E.F. conceived the project and designed experiments; D.R.V., A.S., S.M.,
E.P., E.F. performed experiments; F.C., D.R.V., E.F. analyzed the bioinformatical data; O.D.
contributed to scientific discussion; P.R. provided reagents; C.A.R., E.F. and H.V.O. provided
funding; E.F. wrote the manuscript which has been revised by all authors.

- 599
- 600 Figure legends:
- 601

602Table S1: Level of expression of DEGs with $log_2FC>1$ (P < 0.05, FDR corrected using603Benjamini Horchberg method) in the 6 different conditions of siRNA.

Table S2: Gene ontology analysis of DEGs in si*CCM2* HUVECs with $log_2FC>1$ (*P* < 0.05, FDR corrected using Benjamini Horchberg method).

Table S3: Gene sets of Senescence and SASP used for GSEA analyses.

607Table S4: Lists of DEGs with $log_2FC>1$ (P < 0.05, FDR corrected using Benjamini608Horchberg method) in siCCM2 rescued by ROCKs.

609 Table S5: Gene Ontology Analysis on DEGs with Log₂FC>1 rescued by ROCKs.

610 Table S6: Cytokines upregulated with FC>2 in si*CCM2* HUVECs and their biological

611 effects on immune and endothelial cells.

612 **References**

613 614 615 616 617	1.	Clatterbuck RE, Eberhart CG, Crain BJ, Rigamonti D. Ultrastructural and immunocytochemical evidence that an incompetent blood-brain barrier is related to the pathophysiology of cavernous malformations. J Neurol Neurosurg Psychiatry [Internet]. 2001 Aug [cited 2016 Apr 4];71(2):188–92. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11459890
618 619 620	2.	Labauge P, Denier C, Bergametti F, Tournier-Lasserve E. Genetics of cavernous angiomas. Lancet Neurol [Internet]. 2007 Mar [cited 2016 Apr 28];6(3):237–44. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17303530
621 622 623	3.	Awad IA, Polster SP. Cavernous angiomas: deconstructing a neurosurgical disease. J Neurosurg [Internet]. 2019 Jul 1 [cited 2019 Sep 15];131(1):1–13. Available from: http://www.ncbi.nlm.nih.gov/pubmed/31261134
624 625 626 627	4.	Riant F, Bergametti F, Fournier HD, Chapon F, Michalak-Provost S, Cecillon M, et al. CCM3 mutations are associated with early-onset cerebral hemorrhage and multiple meningiomas. Mol Syndromol [Internet]. 2013 Apr [cited 2020 Jun 30];4(4):165–72. Available from: /pmc/articles/PMC3666455/?report=abstract
628 629 630 631	5.	Shenkar R, Shi C, Rebeiz T, Stockton RA, McDonald DA, Mikati AG, et al. Exceptional aggressiveness of cerebral cavernous malformation disease associated with PDCD10 mutations. Genet Med [Internet]. 2015 Mar 14 [cited 2017 Jun 1];17(3):188– 96. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25122144
632 633 634 635	6.	Labauge P, Brunereau L, Lévy C, Laberge S, Houtteville JP. The natural history of familial cerebral cavernomas: A retrospective MRI study of 40 patients. Neuroradiology [Internet]. 2000 [cited 2020 Jun 30];42(5):327–32. Available from: https://pubmed-ncbi-nlm-nih-gov.proxy.insermbiblio.inist.fr/10872151/
636 637 638 639 640 641	7.	McDonald DA, Shenkar R, Shi C, Stockton RA, Akers AL, Kucherlapati MH, et al. A novel mouse model of cerebral cavernous malformations based on the two-hit mutation hypothesis recapitulates the human disease. Hum Mol Genet [Internet]. 2011;20(2):211–22. Available from: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Cit ation&list_uids=20940147
642 643 644 645 646	8.	Pagenstecher A, Stahl S, Sure U, Felbor U. A two-hit mechanism causes cerebral cavernous malformations: Complete inactivation of CCM1, CCM2 or CCM3 in affected endothelial cells. Hum Mol Genet [Internet]. 2009 [cited 2020 Dec 17];18(5):911–8. Available from: https://pubmed-ncbi-nlm-nih-gov.insb.bib.cnrs.fr/19088124/
647 648	9.	Rath M, Pagenstecher A, Hoischen A, Felbor U. Postzygotic mosaicism in cerebral cavernous malformation. J Med Genet. 2020 Mar 1;57(3):212–6.
649 650 651 652	10.	Detter MR, Snellings DA, Marchuk DA. Cerebral cavernous malformations develop through clonal expansion of mutant endothelial cells. Circ Res [Internet]. 2018 [cited 2020 Jun 30];123(10):1143–51. Available from: https://pubmed-ncbi-nlm-nih-gov.proxy.insermbiblio.inist.fr/30359189/
653	11.	Malinverno M, Maderna C, Abu Taha A, Corada M, Orsenigo F, Valentino M, et al.

654 655 656		Endothelial cell clonal expansion in the development of cerebral cavernous malformations. Nat Commun [Internet]. 2019 Dec 24 [cited 2019 Jul 16];10(1):2761. Available from: http://www.ncbi.nlm.nih.gov/pubmed/31235698
657 658 659 660 661	12.	Bicer A, Guclu B, Ozkan A, Kurtkaya O, Koc DY, Necmettin Pamir M, et al. Expressions of angiogenesis associated matrix metalloproteinases and extracellular matrix proteins in cerebral vascular malformations. J Clin Neurosci [Internet]. 2010 Feb [cited 2020 Jun 30];17(2):232–6. Available from: https://pubmed-ncbi-nlm-nih- gov.proxy.insermbiblio.inist.fr/20036554/
662 663 664 665	13.	Zhou Z, Tang AT, Wong W-Y, Bamezai S, Goddard LM, Shenkar R, et al. Cerebral cavernous malformations arise from endothelial gain of MEKK3-KLF2/4 signalling. Nature [Internet]. 2016 Apr 7 [cited 2016 May 11];532(7597):122–6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27027284
666 667 668 669 670	14.	Fujimura M, Watanabe M, Shimizu H, Tominaga T. Expression of matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinase (TIMP) in cerebral cavernous malformations: Immunohistochemical analysis of MMP-2, -9 and TIMP-2. Acta Neurochir (Wien) [Internet]. 2007 Feb [cited 2020 Jul 1];149(2):179–83. Available from: https://pubmed-ncbi-nlm-nih-gov.insb.bib.cnrs.fr/17043747/
671 672 673 674 675	15.	Noshiro S, Mikami T, Kataoka-Sasaki Y, Sasaki M, Ohnishi H, Ohtaki S, et al. Co- expression of tissue factor and IL-6 in immature endothelial cells of cerebral cavernous malformations. J Clin Neurosci [Internet]. 2017 Mar 1 [cited 2020 Jun 30];37:83–90. Available from: https://pubmed-ncbi-nlm-nih- gov.proxy.insermbiblio.inist.fr/28087183/
676 677 678 679	16.	Goitre L, Balzac F, Degani S, Degan P, Marchi S, Pinton P, et al. KRIT1 regulates the homeostasis of intracellular reactive oxygen species. PLoS One [Internet]. 2010 [cited 2020 Jun 30];5(7):1–22. Available from: https://pubmed-ncbi-nlm-nih-gov.insb.bib.cnrs.fr/20668652/
680 681 682 683	17.	Marchi S, Corricelli M, Trapani E, Bravi L, Pittaro A, Delle Monache S, et al. Defective autophagy is a key feature of cerebral cavernous malformations. EMBO Mol Med [Internet]. 2015 Nov [cited 2020 Jun 30];7(11):1403–17. Available from: https://pubmed-ncbi-nlm-nih-gov.insb.bib.cnrs.fr/26417067/
684 685 686 687	18.	Maddaluno L, Rudini N, Cuttano R, Bravi L, Giampietro C, Corada M, et al. EndMT contributes to the onset and progression of cerebral cavernous malformations. Nature [Internet]. 2013 Jun 9 [cited 2017 Mar 27];498(7455):492–6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23748444
688 689 690 691	19.	Faurobert E, Rome C, Lisowska J, Manet-Dupé S, Boulday G, Malbouyres M, et al. CCM1-ICAP-1 complex controls β 1 integrin-dependent endothelial contractility and fibronectin remodeling. J Cell Biol [Internet]. 2013/08/07. 2013;202(3):545–61. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23918940
692 693	20.	Renz M, Otten C, Faurobert E, Rudolph F, Zhu Y, Boulday G, et al. Regulation of β 1 Integrin-Klf2-Mediated Angiogenesis by CCM Proteins. Dev Cell. 2015;32(2).
694 695 696	21.	Uhlik MT, Abell AN, Johnson NL, Sun W, Cuevas BD, Lobel-Rice KE, et al. Rac- MEKK3-MKK3 scaffolding for p38 MAPK activation during hyperosmotic shock. Nat Cell Biol [Internet]. 2003 Dec [cited 2016 Apr 9];5(12):1104–10. Available from:

- 697 http://www.ncbi.nlm.nih.gov/pubmed/14634666
- 22. Zhou Z, Rawnsley DR, Goddard LM, Pan W, Cao X-J, Jakus Z, et al. The Cerebral
 Cavernous Malformation Pathway Controls Cardiac Development via Regulation of
 Endocardial MEKK3 Signaling and KLF Expression. Dev Cell [Internet]. 2015 Jan 26
 [cited 2017 Sep 6];32(2):168–80. Available from:
- 702http://www.ncbi.nlm.nih.gov/pubmed/25625206
- Cuttano R, Rudini N, Bravi L, Corada M, Giampietro C, Papa E, et al. KLF4 is a key
 determinant in the development and progression of cerebral cavernous malformations.
 EMBO Mol Med [Internet]. 2016 Jan 1 [cited 2017 Mar 27];8(1):6–24. Available from:
 http://www.ncbi.nlm.nih.gov/pubmed/26612856
- Tang AT, Choi JP, Kotzin JJ, Yang Y, Hong CC, Hobson N, et al. Endothelial TLR4
 and the microbiome drive cerebral cavernous malformations. Nature [Internet]. 2017
 May 10 [cited 2017 May 23];545(7654):305–10. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28489816
- Li J, Zhao Y, Coleman P, Chen J, Ting KK, Choi JP, et al. Low fluid shear stress
 conditions contribute to activation of cerebral cavernous malformation signalling
 pathways. Biochim Biophys Acta Mol Basis Dis [Internet]. 2019 Nov 29 [cited 2019
 Aug 27];1865(11):165519. Available from:
 http://www.ncbi.nlm.nib.gov/pubmed/31360810
- 715 http://www.ncbi.nlm.nih.gov/pubmed/31369819
- Whitehead KJ, Chan AC, Navankasattusas S, Koh W, London NR, Ling J, et al. The
 cerebral cavernous malformation signaling pathway promotes vascular integrity via
 Rho GTPases. Nat Med [Internet]. 2009;15(2):177–84. Available from:
 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Cit
 ation&list_uids=19151728
- 27. Borikova AL, Dibble CF, Sciaky N, Welch CM, Abell AN, Bencharit S, et al. Rho
 kinase inhibition rescues the endothelial cell cerebral cavernous malformation
 phenotype. J Biol Chem [Internet]. 2010;285(16):11760–4. Available from:
 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Cit
 ation&list_uids=20181950
- Stockton RA, Shenkar R, Awad IA, Ginsberg MH. Cerebral cavernous malformations
 proteins inhibit Rho kinase to stabilize vascular integrity. J Exp Med [Internet].
 2010;207(4):881–96. Available from:
- http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Cit
 ation&list_uids=20308363
- 29. Lisowska J, Rödel CJ, Manet S, Miroshnikova YA, Boyault C, Planus E, et al. The
 CCM1–CCM2 complex controls complementary functions of ROCK1 and ROCK2
 that are required for endothelial integrity. J Cell Sci [Internet]. 2018 Aug 1 [cited 2018
 Oct 9];131(15):jcs216093. Available from:
- 735 http://www.ncbi.nlm.nih.gov/pubmed/30030370
- 30. McDonald DA, Shi C, Shenkar R, Stockton RA, Liu F, Ginsberg MH, et al. Fasudil
 decreases lesion burden in a murine model of cerebral cavernous malformation disease.
 Stroke [Internet]. 2011/10/29. 2012;43(2):571–4. Available from:
- 739 http://www.ncbi.nlm.nih.gov/pubmed/22034008

31. Shenkar R, Shi C, Austin C, Moore T, Lightle R, Cao Y, et al. RhoA Kinase Inhibition 740 With Fasudil Versus Simvastatin in Murine Models of Cerebral Cavernous 741 Malformations. Stroke [Internet]. 2017 Jan [cited 2016 Dec 31];48(1):187-94. 742 Available from: http://www.ncbi.nlm.nih.gov/pubmed/27879448 743 32. Polster SP, Stadnik A, Akers AL, Cao Y, Christoforidis GA, Fam MD, et al. 744 Atorvastatin Treatment of Cavernous Angiomas with Symptomatic Hemorrhage 745 Exploratory Proof of Concept (AT CASH EPOC) Trial. Neurosurgery [Internet]. 2019 746 747 [cited 2020 Apr 24];85(6):843–53. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30476251 748 Paez-Ribes M, González-Gualda E, Doherty GJ, Muñoz-Espín D. Targeting senescent 749 33. cells in translational medicine. EMBO Mol Med [Internet]. 2019 Dec [cited 2020 Jun 750 30];11(12). Available from: https://pubmed-ncbi-nlm-nih-751 gov.proxy.insermbiblio.inist.fr/31746100/ 752 Zawistowski JS, Stalheim L, Uhlik MT, Abell AN, Ancrile BB, Johnson GL, et al. 753 34. CCM1 and CCM2 protein interactions in cell signaling: implications for cerebral 754 cavernous malformations pathogenesis. Hum Mol Genet [Internet]. 2005;14(17):2521-755 31. Available from: 756 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Cit 757 758 ation&list_uids=16037064 Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and 759 35. 760 Powerful Approach to Multiple Testing. J R Stat Soc Ser B. 1995 Jan;57(1):289–300. 36. Campisi J. Aging, Cellular Senescence, and Cancer. Annu Rev Physiol [Internet]. 2013 761 762 Feb 10 [cited 2020 Jun 30];75(1):685-705. Available from: https://pubmed-ncbi-nlmnih-gov.proxy.insermbiblio.inist.fr/23140366/ 763 764 37. Hernandez-Segura A, de Jong T V, Melov S, Guryev V, Campisi J, Demaria M. Unmasking Transcriptional Heterogeneity in Senescent Cells. Curr Biol [Internet]. 765 2017 Sep 11 [cited 2019 Nov 7];27(17):2652-2660.e4. Available from: 766 http://www.ncbi.nlm.nih.gov/pubmed/28844647 767 Casella G, Munk R, Kim KM, Piao Y, De S, Abdelmohsen K, et al. Transcriptome 768 38. signature of cellular senescence. Nucleic Acids Res [Internet]. 2019 Oct 15 [cited 2019 769 770 Nov 7]; Available from: https://academic.oup.com/nar/advancearticle/doi/10.1093/nar/gkz879/5587628 771 39. De Cecco M, Ito T, Petrashen AP, Elias AE, Skvir NJ, Criscione SW, et al. L1 drives 772 IFN in senescent cells and promotes age-associated inflammation. Nature [Internet]. 773 2019 Feb 7 [cited 2020 Jun 30];566(7742):73-8. Available from: https://pubmed-ncbi-774 nlm-nih-gov.insb.bib.cnrs.fr/30728521/ 775 40. Ly DH, Lockhart DJ, Lerner RA, Schultz PG. Mitotic misregulation and human aging. 776 Science (80-) [Internet]. 2000 Mar 31 [cited 2021 Jan 6];287(5462):2486–92. 777 Available from: https://pubmed-ncbi-nlm-nih-gov.insb.bib.cnrs.fr/10741968/ 778 779 41. Matjusaitis M, Chin G, Sarnoski EA, Stolzing A. Biomarkers to identify and isolate senescent cells [Internet]. Vol. 29, Ageing Research Reviews. Elsevier Ireland Ltd; 780 2016 [cited 2020 Jun 30]. p. 1-12. Available from: https://pubmed-ncbi-nlm-nih-781 gov.insb.bib.cnrs.fr/27212009/ 782

- Faget D V., Ren Q, Stewart SA. Unmasking senescence: context-dependent effects of
 SASP in cancer [Internet]. Vol. 19, Nature Reviews Cancer. Nature Publishing Group;
 2019 [cited 2020 Jun 30]. p. 439–53. Available from: https://pubmed-ncbi-nlm-nihgov.proxy.insermbiblio.inist.fr/31235879/
- 43. Coppé J-P, Desprez P-Y, Krtolica A, Campisi J. The Senescence-Associated Secretory
 Phenotype: The Dark Side of Tumor Suppression. Annu Rev Pathol Mech Dis
 [Internet]. 2010 Jan [cited 2019 Jan 5];5(1):99–118. Available from:
 http://www.ncbi.nlm.nih.gov/pubmed/20078217
- 44. Chan AC, Drakos SG, Ruiz OE, Smith AC, Gibson CC, Ling J, et al. Mutations in 2 distinct genetic pathways result in cerebral cavernous malformations in mice. J Clin Invest [Internet]. 2011;121(5):1871–81. Available from: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Cit ation&list_uids=21490399
- 45. Shi C, Shenkar R, Du H, Duckworth E, Raja H, Batjer HH, et al. Immune Response in Human Cerebral Cavernous Malformations. Stroke [Internet]. 2009 May 1 [cited 2021 Jan 7];40(5):1659–65. Available from: https://pubmed-ncbi-nlm-nihgov.insb.bib.cnrs.fr/19286587/
- 46. Lampugnani MG, Orsenigo F, Rudini N, Maddaluno L, Boulday G, Chapon F, et al.
 CCM1 regulates vascular-lumen organization by inducing endothelial polarity. J Cell
 Sci [Internet]. 2010;123(Pt 7):1073–80. Available from:
 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Cit
 ation&list_uids=20332120
- Rhinn M, Ritschka B, Keyes WM. Cellular senescence in development, regeneration and disease. Dev [Internet]. 2019 [cited 2020 Jul 1];146(20). Available from: https://pubmed-ncbi-nlm-nih-gov.proxy.insermbiblio.inist.fr/31575608/
- Kim H, Rubinsztein DC, Lee JE. Autophagy, cellular aging and age-related human diseases [Internet]. Vol. 28, Experimental Neurobiology. Korean Society for Neurodegenerative Disease; 2019 [cited 2020 Jul 1]. p. 643–57. Available from: https://pubmed-ncbi-nlm-nih-gov.insb.bib.cnrs.fr/31902153/
- 49. Salazar G. NADPH oxidases and mitochondria in vascular senescence [Internet]. Vol.
 19, International Journal of Molecular Sciences. MDPI AG; 2018 [cited 2020 Jul 1].
 Available from: https://pubmed-ncbi-nlm-nih-gov.insb.bib.cnrs.fr/29710840/
- Freund A, Patil CK, Campisi J. p38MAPK is a novel DNA damage responseindependent regulator of the senescence-associated secretory phenotype. EMBO J
 [Internet]. 2011 Apr 20 [cited 2020 Jul 1];30(8):1536–48. Available from:
 http://emboj.embopress.org/cgi/doi/10.1038/emboj.2011.69
- S1. Yuedi D, Houbao L, Pinxiang L, Hui W, Min T, Dexiang Z. KLF2 induces the
 senescence of pancreatic cancer cells by cooperating with FOXO4 to upregulate p21.
 Exp Cell Res [Internet]. 2020 Mar 1 [cited 2020 Jun 26];388(1). Available from:
 https://pubmed-ncbi-nlm-nih-gov.proxy.insermbiblio.inist.fr/31866399/
- 52. Xu Q, Liu M, Zhang J, Xue L, Zhang G, Hu C, et al. Overexpression of KLF4
 promotes cell senescence through microRNA-203-survivin-p21 pathway. Oncotarget
 [Internet]. 2016 [cited 2020 Jun 26];7(37):60290–302. Available from: https://pubmed-

- 826 ncbi-nlm-nih-gov.proxy.insermbiblio.inist.fr/27531889/
- Balistreri CR, Ruvolo G, Lio D, Madonna R. Toll-like receptor-4 signaling pathway in aorta aging and diseases: "its double nature" [Internet]. Vol. 110, Journal of Molecular and Cellular Cardiology. Academic Press; 2017 [cited 2020 Jul 1]. p. 38–53. Available from: https://pubmed-ncbi-nlm-nih-gov.proxy.insermbiblio.inist.fr/28668304/
- Koskimäki J, Polster SP, Li Y, Romanos S, Srinath A, Zhang D, et al. Common transcriptome, plasma molecules, and imaging signatures in the aging brain and a Mendelian neurovascular disease, cerebral cavernous malformation. GeroScience
 [Internet]. 2020 Jun 17 [cited 2020 Jun 30]; Available from: https://pubmed-ncbi-nlmnih-gov.proxy.insermbiblio.inist.fr/32556941/
- 836 55. Ren AA, Snellings DA, Su YS, Hong CC, Castro M, Tang AT, et al. PIK3CA and
 837 CCM mutations fuel cavernomas through a cancer-like mechanism. Nature [Internet].
 838 2021 Jun 10 [cited 2021 Jul 4];594(7862):271–6. Available from: https://pubmed-ncbi839 nlm-nih-gov.insb.bib.cnrs.fr/33910229/
- S6. Guerrero A, Iglesias C, Raguz S, Floridia E, Gil J, Pombo CM, et al. The cerebral cavernous malformation 3 gene is necessary for senescence induction. Aging Cell
 [Internet]. 2015 Apr 1 [cited 2020 Jul 1];14(2):274–83. Available from: https://pubmed-ncbi-nlm-nih-gov.proxy.insermbiblio.inist.fr/25655101/
- Silbert HTJ, Swift J. The consequences of ageing, progeroid syndromes and cellular
 senescence on mechanotransduction and the nucleus [Internet]. Vol. 378, Experimental
 Cell Research. Elsevier Inc.; 2019 [cited 2021 Jun 24]. p. 98–103. Available from:
 https://pubmed.ncbi.nlm.nih.gov/30836065/
- 58. Kümper S, Mardakheh FK, McCarthy A, Yeo M, Stamp GW, Paul A, et al. Rhoassociated kinase (ROCK) function is essential for cell cycle progression, senescence and tumorigenesis. Elife [Internet]. 2016 Jan 14 [cited 2020 Dec 17];5. Available from: https://pubmed-ncbi-nlm-nih-gov.insb.bib.cnrs.fr/26765561/
- Sp. Zhang J, Rigamonti D, Dietz HC, Clatterbuck RE. Interaction between krit1 and
 malcavernin: Implications for the pathogenesis of cerebral cavernous malformations.
 Neurosurgery [Internet]. 2007 Feb [cited 2021 Jun 24];60(2):353–9. Available from:
 https://pubmed-ncbi-nlm-nih-gov.insb.bib.cnrs.fr/17290187/
- 60. Glading A, Han J, Stockton RA, Ginsberg MH. KRIT-1/CCM1 is a Rap1 effector that
 regulates endothelial cell cell junctions. J Cell Biol [Internet]. 2007;179(2):247–54.
 Available from:
- http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Cit
 ation&list_uids=17954608
- 861 61. Tanaka T, Nishimura D, Wu R-C, Amano M, Iso T, Kedes L, et al. Nuclear Rho
 862 kinase, ROCK2, targets p300 acetyltransferase. J Biol Chem [Internet]. 2006 Jun 2
 863 [cited 2019 Jan 5];281(22):15320–9. Available from:
 864 http://www.jbc.org/lookup/doi/10.1074/jbc.M510954200
- Chen W, Nyuydzefe MS, Weiss JM, Zhang J, Waksal SD, Zanin-Zhorov A. ROCK2,
 but not ROCK1 interacts with phosphorylated STAT3 and co-occupies TH17/TFH
 gene promoters in TH17-activated human T cells. Sci Rep [Internet]. 2018 Dec 1 [cited
 2021 Apr 8];8(1). Available from: https://pubmed-ncbi-nlm-nih-

- 869 gov.proxy.insermbiblio.inist.fr/30413785/
- 870 63. Vaeyens MM, Jorge-Peñas A, Barrasa-Fano J, Steuwe C, Heck T, Carmeliet P, et al.
 871 Matrix deformations around angiogenic sprouts correlate to sprout dynamics and
 872 suggest pulling activity. Angiogenesis. 2020;
- Finch-Edmondson M, Sudol M. Framework to function: Mechanosensitive regulators
 of gene transcription [Internet]. Vol. 21, Cellular and Molecular Biology Letters.
 BioMed Central Ltd.; 2016 [cited 2020 Jul 1]. Available from: https://pubmed-ncbinlm-nih-gov.proxy.insermbiblio.inist.fr/28536630/
- Torrino S, Roustan F, Kaminski L, Bertero T, Pisano S, Ambrosetti D, et al. UBTD1 is
 a mechano-regulator controlling cancer aggressiveness. EMBO Rep [Internet]. 2019
 Apr [cited 2021 Apr 7];20(4). Available from: https://pubmed-ncbi-nlm-nihgov.proxy.insermbiblio.inist.fr/30804013/
- 881 66. SenBanerjee S, Lin Z, Atkins GB, Greif DM, Rao RM, Kumar A, et al. KLF2 is a
 882 novel transcriptional regulator of endothelial proinflammatory activation. J Exp Med.
 883 2004 May 17;199(10):1305–15.
- Jia Z min, Ai X, Teng J fei, Wang Y peng, Wang B jun, Zhang X. p21 and CK2
 interaction-mediated HDAC2 phosphorylation modulates KLF4 acetylation to regulate
 bladder cancer cell proliferation. Tumor Biol [Internet]. 2016 Jun 1 [cited 2021 Apr
 7];37(6):8293–304. Available from: https://pubmed.ncbi.nlm.nih.gov/26729194/
- 888 68. Varet H, Brillet-Guéguen L, Coppée JY, Dillies MA. SARTools: A DESeq2- and
 889 edgeR-based R pipeline for comprehensive differential analysis of RNA-Seq data.
 890 PLoS One [Internet]. 2016 Jun 1 [cited 2020 Jul 2];11(6). Available from:
 891 https://pubmed-ncbi-nlm-nih-gov.proxy.insermbiblio.inist.fr/27280887/
- 69. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for
 RNA-seq data with DESeq2. Genome Biol [Internet]. 2014 Dec 5 [cited 2020 Jul
 2];15(12). Available from: https://pubmed-ncbi-nlm-nih-gov.insb.bib.cnrs.fr/25516281/
- 895 70. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al.
 896 Gene set enrichment analysis: A knowledge-based approach for interpreting genome897 wide expression profiles. Proc Natl Acad Sci U S A [Internet]. 2005 Oct 25 [cited 2020
 898 Jul 2];102(43):15545–50. Available from: https://pubmed-ncbi-nlm-nih899 gov.proxy.insermbiblio.inist.fr/16199517/
- 900 71. Pfaffl MW, Tichopad A, Prgomet C, Neuvians TP. Determination of stable
 901 housekeeping genes, differentially regulated target genes and sample integrity:
 902 BestKeeper--Excel-based tool using pair-wise correlations. Biotechnol Lett [Internet].
 903 2004 Mar [cited 2016 Apr 29];26(6):509–15. Available from:
 904 http://www.ncbi.nlm.nih.gov/pubmed/15127793
- Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, et al.
 Accurate normalization of real-time quantitative RT-PCR data by geometric averaging
 of multiple internal control genes. Genome Biol [Internet]. 2002 Jun 18 [cited 2016
 Apr 29];3(7):RESEARCH0034. Available from:
 http://www.ncbi.nlm.nib.gov/pubmed/1218/4808
- 909http://www.ncbi.nlm.nih.gov/pubmed/12184808
- 910 73. Sharma VP, Entenberg D, Condeelis J. High-resolution live-cell imaging and time-


lapse microscopy of invadopodium dynamics and tracking analysis. Methods Mol Biol 911 [Internet]. 2013 [cited 2020 Jul 2];1046:343–57. Available from: https://pubmed-ncbi-912 913 nlm-nih-gov.proxy.insermbiblio.inist.fr/23868599/ Ranga A, Gobaa S, Okawa Y, Mosiewicz K, Negro A, Lutolf MP. 3D niche 914 74. 915 microarrays for systems-level analyses of cell fate. Nat Commun [Internet]. 2014 Jul 14 [cited 2020 Jul 6];5. Available from: https://pubmed.ncbi.nlm.nih.gov/25027775/ 916 917 75. Lutolf MP, Lauer-Fields JL, Schmoekel HG, Metters AT, Weber FE, Fields GB, et al. 918 Synthetic matrix metalloproteinase-sensitive hydrogels for the conduction of tissue regeneration: Engineering cell-invasion characteristics. Proc Natl Acad Sci U S A 919 [Internet]. 2003 Apr 29 [cited 2020 Jul 6];100(9):5413–8. Available from: 920 https://pubmed.ncbi.nlm.nih.gov/12686696/ 921

922


A

В

G.O. Cellular component



G.O. Biological process






Figure 1: The loss of CCM2 turns on a SASP transcriptomic program.

(A) Gene Ontology enrichment analysis of cellular components in downregulated and upregulated genes in siCCM2 HUVEC compared to siNT HUVEC, bar graphs represent the fold enrichment. (B) Gene Ontology enrichment analysis of biological functions in downregulated and upregulated genes in siCCM2 HUVEC compared to siNT HUVEC, bar graphs represent the fold enrichment. (C) Schematic representation of the of enriched pathways in siCCM2 HUVEC with their reactome identification numbers. (D) GSEA profiles showing a significant normalized enrichment score (NES) of gene sets associated with replicative senescence (37) and SASP (39) in siCCM2 HUVEC transcriptome.




Figure 2: CCM2-depleted EC display hallmarks of SASP.

(A) Representative images of DAPI and SA-ßgalactosidase staining of siNT and siCCM2 HUVEC. (Middle) Merge of DAPI and SA-β-galactosidase stainings at higher magnification. (B) Quantification of the % of positive cells for SA- β -galactosidase. Error bars are means ± SEM from 6 independent experiments. (C) Representative images of merged DAPI and HIRA stainings of siNT and siCCM2 HUVEC. (D) Quantification of the % of HIRA positive cells. Error bars are means ± SEM from 5 independent experiments. (E) Histogram of the cell population in function of their nucleus area. Error bars are means ± SEM from 4 independent experiments. (F) Boxplots of the read counts for p21/CIP and p15/INK4b mRNA. Error bars are means ± SEM from 3 independent experiments. (G) Representative plot showing BrdU incorporation as a function of total DNA content. The percentage of cells in each phase of the cell cycle is indicated. (H) Proliferation rate of siRNA transfected HUVEC measured by impedance using XCELLigence. Error bars are means ± SEM from 4 independent experiments. (I) Representative images of the proliferation marker Ki-67 staining (green) merged with DAPI staining. (J) Quantification of the percentage of cells positive for Ki-67 staining. Error bars are means ± SEM from 7 independent experiments. (K) Heatmap of expression of ECM remodelling proteins (left) (see Fig S4 for enlarged panel) and of SASP factors (right) over the 2 siRNA conditions, 3 biological replicates per condition. (*) P-value<0.05; (**) P-value<0.005; (***) P-value<0.0005; (****) P-value<0.00005. Scale bars are equal to 10 μm.





Figure 3: The loss of KRIT similarly to that of CCM2 leads to senescence in ECs whereas the loss of CCM3 does not.

Representative merged images of DAPI and SA-β-galactosidase stainings in HUVECs (A) and HBMVECs (C). Quantification of the % of positive cells for SA-β-galactosidase in HUVECs (B) and HBMVECs (D). Error bars are means ± SEM from 5 (HUVECs) or 3 (HBMVECs) independent experiments. Representative images of merged DAPI and HIRA stainings for HUVECs (E) and HBMVECs (G). Quantification of the % of HIRA positive cells in HUVECs (F) and HBMVECs (H). Error bars are means ± SEM from 3 (2 for KRIT) (HUVECs) and 3 (HBMVECs) independent experiments. Representative images of the proliferation marker Ki-67 staining (green) merged with DAPI staining in HUVECs (I) and HBMVECs (K). Quantification of the percentage of cells positive for Ki-67 staining for HUVECs (J) and HBMVECs (L). Error bars are means ± SEM from 3 (2 for KRIT) (HUVECs) and 3 (HBMVECs) independent experiments Proliferation rate of siRNA transfected HUVECs (M) and HBMVECs (N) measured by impedance using XCELLigence. Errors bars are means ± SEM from 6 to 12 technical replicates over 3 independent experiments.





A

С

Figure 4: ROCK2 controls the SASP transcriptomic program of CCM2-depleted EC

(A) Venn diagrams showing overlap of DEGs with $FC \ge 2$; P < 0.05 in siCCM2 HUVEC (grey) with DEG rescued in siCCM2+siROCK1(Blue) siCCM2+siROCK2 (Green). (B) Heatmap of the DEGs with FC≥ 2; P < 0.05 restored in common by ROCK1 and ROCK2. Upregulated (left) and downregulated (right) genes over the 6 siRNA conditions, 3 biological replicates per condition. (C) Clustered heatmap of GO enriched in upand down-regulated genes in siCCM2 HUVEC. (D) GSEA enrichment plot showing the loss of significant enrichment in replicative senescence signature in siCCM2+ROCK2 but not in siCCM2+ROCK1 HUVEC transcriptome.

score (ES) 0.3

nrich - 0.1

0.2

0.1

0.0

NES = 1.34 p-value=0.071

0.2

G 0.1

e 0.0

- 0.1 - 0.2 - 0.3

NES = -1.29 p-value=0.05




Figure 5: ROCKs dysfunctions induce premature senescence in CCM2-depleted ECs.

(A) Representative images of SA- β -galactosidaseand DAPI stainings of siRNA-transfected HUVECs treated or not with blebbistatin or Y27632 at 10 μM. (B) Quantification of the % of positive cells for SA-β-galactosidase. Error bars are means± SEM from 3 independent experiments. (C) Quantification of the % of HIRA positive cells in siRNA-transfected HUVECs treated or not with blebbistatin or Y27632. Error bars are means \pm SEM from 4 (drug treatments) and 3 (ROCKs silencing) independent experiments. (D) Boxplots of the read counts for p21/CIP and p15/INK4b after depletion of ROCK1 or ROCK2. Error bars are means ± SEM from 3 independent experiments. (E) Quantification by BrdU assay of the percentage of cells in each phase of the cell cycle for siRNA-transfected HUVECs treated or not with blebbistatin or Y27632. Error bars are means ± SEM from 5 (drug treatments) and 8 (ROCKs silencing) independent experiments. (F) Quantification of the percentage of cells positive for Ki-67 staining. Error bars are means ± SEM from 5 (drug treatments) to 4 (ROCKs silencing) independent experiments. (G) Heatmap of expression of ECM remodelling proteins (left) and of SASP factors (right) over the 4 siRNA conditions, 3 biological replicates per condition. (*) P-value<0.05; (**) P-value<0.005; (***) P-value<0.0005; (****) P-value<0.0005. Scale bars are equal to 10 µm. Data for siNT and siCCM2 HUVECs are the same as in figure 2.






Figure 6: ROCK1 causes ECM degradation and invasion by CCM2-depleted HUVECs and neighbouring WT EC while ROCK2 causes chemo-attraction of WT ECs and macrophages.

(A) Representative images of the degradation of fluorescent gelatin by siRNA transfected HUVECs treated or not with GM6001, blebbistatin or Y-27632. Scale bars, 10µm. (B) Quantification of the area of gelatin degradation. Error bars are means ± SEM from 3 (drug treatments) or 5 (silencing of ROCKs) independent experiments. (C) Representative images of siRNA transfected GFP-HUVECs after invasion of 3D-PEG gels. Yellow squares are magnified zones of the images. Yellow arrows point at isolated invading cells. Scale bars, 50µm. (D) Quantification of the maximum invasion distance of siRNA transfected HUVECs treated or not with blebbistatin. Error bars are means ± SEM from 3 independent experiments (2 to 3 technical replicates per condition) for siRNA transfected HUVECs and 2 for blebbistatin treated HUVECs. (E) Representative images of siRNA transfected GFP-HUVECs and RFP WT-HUVECs after invasion of 3D-PEG gels Scale bar, 50µm. (F) Quantification of the maximum invasion distance of RFP WT-HUVECs. Error bars are means ± SEM from 3 independent experiments (2 to 3 technical replicates per condition). (G) Quantification of the rate of invasion of WT HUVECs upon chemo-attraction by conditioned media of siRNA-transfected cells measured in a modified Boyden chamber in real time using xCELLigence. Error bars are means ± SEM from 3 independent experiments (2-4 technical replicates per condition). (H) Quantification of the rate of transmigration of IMAC macrophages upon chemo-attraction by conditioned media of siRNA-transfected cells measured in a modified Boyden chamber in real time using xCELLigence. Error bars are means \pm SEM from 3 independent experiments.

(*) P-value<0.05; (**) P-value<0.005; (***) P-value<0.0005; (****) P-value<0.0005.

ROCKs-dependent Senescence-Associated with Secretory Phenotype





С

FigS1: Validation of the silencing of the target genes by siRNA in HUVECs and HBMVECs






Fig S2: GSEA analyses using different gene sets of senescence.

Comparison of the enrichment in different senescence and SASP signatures(38,40) in siCCM2, siCCM2+ROCK1 and siCCM2+ROCK2.



FigS3: Boxplots of the expression level of cell cycle regulators

in the 6 siRNA conditions, 3 biological replicates per condition, as measured by RNA seq.



ECM remodellers (66 genes)

Fig S4 : Heatmap of expression of ECM remodelling proteins over the 4 siRNA conditions, 3 biological replicates per condition.

HBMVECs





Fig S5: Effects of ROCKs silencing or drug treatments on the acto-adhesive phenotype of siCCM2 HBMVECs and HUVECs and on senescence marks in siNT HUVECs

(A) Representative immunofluorescence images of F-actin and β -catenin stainings in siRNA transfected HBMVECs. Scale bar 10 μ m.

(B) Representative immunofluorescence images of the actin cytoskeleton of CCM2 transfected HUVECs treated or not with Blebbistatin or Y-27632, scale bar 10 μ m. Effects these drugs on SA- β -galactosidase activity (C) cell cycle progression (D) and Ki67 staining (E) of siNT HUVECs.

(F) Representative immunofluorescence images of β 1 integrin staining in siRNA transfected HUVECs treated or not with Blebbistatin or Y-27632. Scale bar 10 μ m









Figure S6: ROCKs dysfunctions induce senescence marks in CCM2-depleted HBMVECs.

(A) Quantification of the % of cells positive for SA- β -galactosidase in siRNA-transfected HBMVECs treated or not with blebbistatin or Y-27632. Error bars are means \pm SEM from 3 independent experiments. (B) Quantification of the % of cells positive for Ki-67 staining in siRNA-transfected HBMVECs treated or not with

blebbistatin or Y-27632. Error bars are means \pm SEM from 3 independent experiments. (C) Quantification of the % of HIRA positive cells in siRNA-transfected HBMVECs treated or not with blebbistatin or Y-27632. Error bars are means \pm SEM from 3 independent experiments. (*) P-value<0.05; (**) P-value<0.005; (***) P-value<0.0005; (***) P-value<0.0005; (****) P-value<0.0005; (****) P-value<0.0005. Data for siNT and siCCM2 HBMVECs are the same as in figure 3.

HBMVECs

В



С

Chemoattraction of macrophages





Figure S7 : As in HUVECs, ROCK1 causes ECM degradation by CCM2-depleted HBMVECs and ROCK2 causes chemo-attraction of macrophages.

(A) Representative images of the degradation of fluorescent gelatin by siRNA transfected HBVMECs treated or not with blebbistatin or Y-27632. Scale bars, 10µm. (B) Quantification of the area of gelatin degradation. Error bars are means ± SEM from 3 drug treatments independent

experiments. (C) Quantification of the rate of transmigration of IMAC macrophages measured in a modified Boyden chamber in real time using xCELLigence upon chemo-attraction by conditioned media of siRNA-transfected HBMVECs. Error bars are means ± SEM from 3 independent experiments.

(*) P-value<0.05; (**) P-value<0.005.



FigS8: Heatmap of EndMT markers over the 4 biological conditions